Chemours Reports Q2 2025 Results: Net Sales Rise 4% to $1.6B, Net Loss of $381M; Adjusted EPS at $0.58

Reuters
08/06
Chemours Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Sales Rise 4% to $1.6B, Net Loss of $381M; Adjusted EPS at $0.58

The Chemours Company has released its financial results for the second quarter of 2025, reporting a 4% increase in net sales to $1.615 billion compared to $1.554 billion in the same quarter of the previous year. This growth was mainly driven by a 3% increase in volume and a 1% rise in price, with significant contributions from the Thermal & Specialized Solutions segment, particularly in Opteon™ Refrigerants. The company reported a net loss attributable to Chemours of $381 million for the quarter, compared to a net income of $60 million in the prior-year quarter. This loss was primarily influenced by litigation-related expenses associated with a settlement with the State of New Jersey. Adjusted net income was $87 million, up from $58 million in the same period last year. Adjusted EBITDA showed a significant increase of 22% year-over-year, reaching $253 million compared to $207 million in the previous year's second quarter. Corporate expenses were reduced by $24 million, largely due to lower costs related to internal reviews and material weakness remediation efforts from 2024. In January 2025, Chemours announced a restructuring program under its Advanced Performance Materials segment to exit its SPS Capstone™ business, with final sales expected in the third quarter of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Chemours Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250805063574) on August 05, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10